Skip to main content

Table 12 Assay results for the determination of VPS in its co-formulated tablet with SFV by Method 1

From: Two novel UPLC methods utilizing two different analytical columns and different detection approaches for the simultaneous analysis of velpatasvir and sofosbuvir: application to their co-formulated tablet

Studied drug

Proposed method

Comparison method [11]

Amount taken (ng/mL)

Amount found (ng/mL)

% Found

% Found

Column (A)

Column (B)

Column (A)

Column (B)

Column (A)

Column (B)

Epclusa® tablet (SFV 400 mg/VPS100 mg)

1.0

2.5

0.982

2.449

98.20

97.99

102.45

3.0

5.0

2.995

4.827

99.84

96.53

101.78

5.0

10.0

5.049

9.782

100.97

97.82

98.91

Mean

    

99.67

97.45

101.05

 ±SD

    

1.39

0.80

1.88

t-test

    

2.74

3.05

(2.78)*

F-test

    

1.82

5.55

(19.0)*

  1. Each result is the average of three separate determinations
  2. * The figures between parentheses are the tabulated t and F values at P = 0.05 [17]